Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Abstract:
· NBTXR3 activated by radiotherapy induces a significant adaptive immune pattern versus radiotherapy alone in patients with soft tissue sarcoma
· Patients treated with NBTXR3 and radiotherapy show a marked increase of PD1 and CD8 infiltration
· Preclinical data on different animal models confirm broad potential of NBTXR3 as a primer of the immune response
· Strong data to support the rational for the upcoming clinical trial in combination with check point inhibitors.

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Paris, France and Cambridge, MA | Posted on November 14th, 2017

NANOBIOTIX NANOBIOTIX(Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. These data were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8 to 12, 2017 in National Harbor, Maryland, USA.

Nanobiotix’s lead product, NBTXR3, has a universal physical mode of action which is designed for the local destruction of tumors. In addition to the physical destruction of cancer cells, recently published data suggested that NBTXR3 generates immunogenic cell death which could trigger a specific immune response to attack tumors.

The new clinical data and pre-clinical data indicate that NBTXR3 could play a key role in oncology and could become a backbone of immuno-oncology.

The data Nanobiotix recently presented at SITC from its immuno-oncology programs included:

“Antitumor immunity in patients with locally soft tissue sarcoma treated with hafnium oxide nanoparticles and radiation therapy”[i] -- P 412

In this study, tumors from the ongoing two-arm Phase II/III clinical trial were examined both pre- and post-treatment in patients with locally advanced soft tissue sarcoma who had received either NBTXR3 with radiotherapy (more than 10 patients) or radiotherapy alone (more than 10 patients).

The results observed in the post-treatment examination of patients who received both NBTXR3 and radiotherapy showed a significant increase of CD8+ T cells and a marked increase of CD3+, PD-1 and CD103+ immune cell infiltration. In contrast, there was no difference observed between pre- and post-treatment examination when patients received radiotherapy alone.

Furthermore, a functional analysis of genes up-regulated in NBTXR3 plus Radiotherapy arm showed an enrichment of cytokines, immune checkpoints, T cell activation, and dendritic/macrophages markers.

These promising data confirm that NBTXR3 induces a specific adaptive immune pattern and brings substantial changes to the tumor immune profile in patients with soft tissue sarcoma. As such, it may convert the tumor immunologically and be effectively combined with immunotherapeutic agents across oncology.

These data strengthen the relevance of using NBTXR3 in combination with immune checkpoint inhibitors. In September 2017, Nanobiotix announced the Company’s plan to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S., with a multi-arm trial targeting a sub-population of advanced lung, and head and neck cancer patients.

“Transforming immunologically ‘cold’ tumor into ‘hot’ tumor with hafnium oxide nanoparticles and radiation therapy”[ii] -- P 413

These in vivo pre-clinical studies explored the ability of NBTXR3 to bring substantial immune cell infiltrations in colorectal cancer and breast cancer models, and convert immunologically “cold” tumors into “hot” tumors.

In mice bearing CT26 tumors (murine colorectal cancer cells), a marked increase of cytokine content and immune cell infiltrates was observed with NBTXR3 and radiotherapy compared to radiotherapy alone.

In mice inoculated with 4T1 cells (murine breast cancer model) previously treated with NBTXR3 and radiotherapy, a marked increase of CD8+ was observed in tumors when compared to those in mice inoculated with 4T1 cells treated only with radiotherapy.

Data generated from colorectal and breast cancer tumor models suggest that NBTXR3 triggers immunogenic conversion of the tumor microenvironment regardless of the molecular characteristics of the tumor. These data confirm the broad potential of NBTXR3 as a primer of the immune response.

***

About NANOBIOTIX’s immuno-oncology research program

Many IO combination strategies focus on ‘priming’ the tumor, which is now becoming a prerequisite of turning a “cold” tumor into a “hot” tumor. Compared to other modalities that could be used for priming the tumor, NBTXR3 could have a number of advantages: the physical and universal mode of action that could be used widely across oncology, the one-time local injection and good fit within existing medical practice already used as a basis for cancer treatment, as well as a very good chronic safety profile and well-established manufacturing process.

After more than 18 months of development, the Company presented preclinical proof of concept demonstrating that NBTXR3 actively stimulates the host immune system to attack tumor cells.

Recently, Nanobiotix presented new translational data. Taken together, these non-clinical and preliminary clinical results confirm that NBTXR3 plus radiotherapy could efficiently prime an adaptive antitumor immune response, turning “cold” tumors in “hot” tumors. Additionally, these results suggest that the physically-induced response and subsequent immune activation triggered by the NBTXR3 treatment could be generic.

Results suggests that NBTXR3 with radiotherapy could transform tumors into an effective in situ vaccine, opening up very promising perspectives in the treatment of local cancer and metastases.

On top of the Company’s core development activities, these findings could open new collaborations for NBTXR3 through combinations with other immuno-oncology drugs.

In September 2017, Nanobiotix announced its intention to start a new trial in the company’s immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease.

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

In 2016 the Company started a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company’s Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.

For more information, please click here

Contacts:
Nanobiotix

Sarah Gaubert
Director, Communications & Public Affairs
+33 (0)1 40 26 07 55
/



Noël Kurdi
Director, Investor Relations
+1 (646) 241-4400
/
Media relations

France - Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34



United States – RooneyPartners
Marion Janic
+1 (212) 223-4017


Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Quantum optics allows us to abandon expensive lasers in spectroscopy: Lomonosov Moscow State University scientists have invented a new method of spectroscopy November 21st, 2017

Nano-watch has steady hands November 21st, 2017

Nano Global, Arm Collaborate on Artificial Intelligence Chip to Drive Health Revolution by Capturing and Analyzing Molecular Data in Real Time November 21st, 2017

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

ICN2 researchers compute unprecedented values for spin lifetime anisotropy in graphene November 17th, 2017

Cancer

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Govt.-Legislation/Regulation/Funding/Policy

EC Project Aims at Creating and Commercializing Cyber-Physical-System Solutions November 14th, 2017

Leti Joins DARPA-Funded Project to Develop Implantable Device for Restoring Vision November 9th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Electrostatic force takes charge in bioinspired polymers November 2nd, 2017

Nanomedicine

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Announcements

Quantum optics allows us to abandon expensive lasers in spectroscopy: Lomonosov Moscow State University scientists have invented a new method of spectroscopy November 21st, 2017

Nano-watch has steady hands November 21st, 2017

Nano Global, Arm Collaborate on Artificial Intelligence Chip to Drive Health Revolution by Capturing and Analyzing Molecular Data in Real Time November 21st, 2017

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Nanobiotechnology

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Age-old malaria treatment found to improve nanoparticle delivery to tumors: Nanomedicine researchers find new use for 70-year-old drug November 7th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project